Total Testing Process applied to therapeutic drug monitoring: Impact on patients' outcomes and economics

Clinical Chemistry

Volumn 44, Issue 2, 1998, Pages 370-374

  Schumacher, Gerald E ^a   Barr, Judith T ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYTOIN; THEOPHYLLINE;

CLINICAL LABORATORY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MONITORING; HUMAN; LABORATORY TEST; PATIENT CARE; PHYSICIAN; PREDICTION; QUALITY CONTROL; TREATMENT OUTCOME;

EID: 0031951484     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.2.370     Document Type: Conference Paper

References (18)

1. Inhorn SL, Addison BV, eds. Proceedings of the 1986 institute on critical issues in health practices: managing the quality of laboratory test results in a changing health center environment. Wilmington, DE: DuPont, 1987.
2. Martin ML, Addison BV, Eagner WM, Essien JDK, eds. Proceedings of the 1989 institute on critical issues in health laboratory practice: improving the quality of health management through clinician and laboratorian teamwork. Wilmington, DE: DuPont, 1991.
3. Barr JT, Silver S. The total testing process and its implications for laboratory administration and education. Clin Lab Manage Rev 1994;8:526-42.
4. Barr JT, Schumacher GE. The total testing process applied to therapeutic drug monitoring. In: Schumacher GE, ed. Therapeutic drug monitoring. East Norwalk, CT: Appleton & Lange, 1995:47-82.
5. Schumacher GE. Introduction to therapeutic drug monitoring. In: Schumacher GE, ed. Therapeutic drug monitoring. East Norwalk, CT: Appleton & Lange, 1995:2.
6. Barr JT, Schumacher GE. Outcomes assessment of therapeutic drug monitoring. In: Schumacher GE, ed. Therapeutic drug monitoring. East Norwalk, CT: Appleton & Lange, 1995:191-236.
7. Epstein AM. The outcomes movement - will it get us where we want to go? N Engl J Med 1990;323:266-70.
8. Ellwood PM. Outcome management: a technology of patient experience. N Engl J Med 1988;318:1549-56.
9. Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966;44:166-206.
10. Schumacher GE, Barr JT. Decision analysis applied to therapeutic drug monitoring. In: Schumacher GE, ed. Therapeutic drug monitoring. East Norwalk, CT: Appleton & Lange, 1995:143-90.
11. Schumacher GE, Barr JT. Using population-based serum drug concentration cut-off values to predict toxicity: test performance and limitations compared with Bayesian interpretation. Clin Pharm 1990;9:88-96.
12. Schumacher GE, Barr JT, Browne TR, Collins JF. Test performance characteristics of the serum phenytoin concentration (SPC): the relationship between SPC and patient response. Ther Drug Monit 1991;13:318-24.
13. Schumacher GE, Barr JT. Applying decision analysis in therapeutic drug monitoring: using decision trees to interpret serum theophylline concentrations. Clin Pharm 1986;5:325-33.
14. Schumacher GE, Barr JT. Making serum drug levels more meaningful. Ther Drug Monit 1989;11:580-4.
15. Schumacher GE, Barr JT. Bayesian and threshold probabilities in therapeutic drug monitoring: when can serum drug concentrations alter clinical decisions? Am J Hosp Pharm 1994;51:321-7.
16. Weinstein MC, Fineberg HV, eds. Clinical decision analysis. Philadelphia: WB Saunders, 1980:105-8.
17. Ried LD, Horn JR, McKenna DA. Therapeutic drug monitoring reduces toxic drug reactions: a meta-analysis. Ther Drug Monit 1990;12:72-8.
18. Destache CJ. Use of therapeutic drug monitoring in pharmacoeconomics. Ther Drug Monit 1993;15:608-10.